"Proteasome Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the function or proteolytic action of the PROTEASOME.
| Descriptor ID |
D061988
|
| MeSH Number(s) |
D27.505.519.389.745.705
|
| Concept/Terms |
Proteasome Inhibitors- Proteasome Inhibitors
- Inhibitors, Proteasome
- Proteasome Inhibitor
- Inhibitor, Proteasome
- Proteasome Endopeptidase Complex Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Proteasome Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Proteasome Inhibitors".
This graph shows the total number of publications written about "Proteasome Inhibitors" by people in this website by year, and whether "Proteasome Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 2 | 4 | 6 |
| 2005 | 6 | 3 | 9 |
| 2006 | 5 | 7 | 12 |
| 2007 | 3 | 4 | 7 |
| 2008 | 4 | 4 | 8 |
| 2009 | 4 | 6 | 10 |
| 2010 | 2 | 2 | 4 |
| 2011 | 5 | 7 | 12 |
| 2012 | 5 | 5 | 10 |
| 2013 | 4 | 3 | 7 |
| 2014 | 3 | 1 | 4 |
| 2015 | 1 | 7 | 8 |
| 2016 | 3 | 7 | 10 |
| 2017 | 4 | 5 | 9 |
| 2018 | 2 | 3 | 5 |
| 2019 | 6 | 5 | 11 |
| 2020 | 3 | 4 | 7 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proteasome Inhibitors" by people in Profiles.
-
Proteasome inhibition for glioblastoma: Lessons learned and new opportunities. Neuro Oncol. 2024 Sep 05; 26(9):1683-1684.
-
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis. J Exp Clin Cancer Res. 2024 Mar 05; 43(1):68.
-
Effectiveness of combined plasma cell therapy and costimulation blockade based desensitization regimen in heart transplant candidates. Clin Transplant. 2024 02; 38(2):e15249.
-
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. Blood Rev. 2023 09; 61:101100.
-
Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 (HDAC3) Stabilization and Chromatin Condensation. Cancer Res Commun. 2022 12; 2(12):1693-1710.
-
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase? 2 trial. Blood Cancer J. 2022 01 24; 12(1):9.
-
The Functional and Mechanistic Roles of Immunoproteasome Subunits in Cancer. Cells. 2021 12 20; 10(12).
-
Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition. Neoplasia. 2022 01; 24(1):1-11.
-
Reducing treatment toxicity in Waldenstr?m macroglobulinemia. Expert Opin Drug Saf. 2021 Jun; 20(6):669-676.
-
Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Nat Commun. 2021 02 15; 12(1):1022.